NuVasive (NUVA) Change of Rating
In a note revealed to clients and investors on Thursday, 4 January, Needham stated it was upgrading NuVasive (NUVA) Stock from a “Underperform” to a “Buy”. The firm has $71.0 target price on NUVA’s stock.
In spite of this rating upgrade NUVA is right now trading 0.00% lower at $0.00 as of 12:04 AM New York time. NuVasive’s stock is 0% in the past 200 days. It has underperformed the S&P 500 Index, which has surged 6.00% in the same time.
Blue Jay Capital Management Llc had the most significant stake with ownership of 129,680 shares as of Q2 2015 for 4.72% of the US long stock exposure. Tiger Legatus Capital Management Llc is another quite bullish investment manager who is possessing 210,000 shares of NuVasive or 4.55% of their US long stock exposure. Furthermore, Hood River Capital Management Llc have 3.68% of their US long stock exposure invested in the company for 538,671 shares. The New York-based fund Iguana Healthcare Management Llc revealed it had purchased so far a stake worth about 2.38% of the investment manager’s stock portfolio in NuVasive. The Maryland-based fund Profit Investment Management Llc is also positive about the stock, possessing 100,000 shares or 2.3% of their US long stock exposure.
NuVasive (NUVA) closed at $0 yesterday. A total of shares of the company’s stock traded hands. This is down from average of shares. NuVasive has a 52 week low of $0.00 and a 52 week high of $0. The company has a market cap of $ and a P/E ratio of 0.
Get the latest NuVasive (NUVA) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Needham Upgrades NuVasive (NUVA) to “Buy” With $71.0 Target Price per Share from “Underperform” Rating Outlook appeared first on Octafinance.